Gabapentin (All indications) updated on 04-22-2025

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19302
R81713		 Beau (Gabapentin) (Indications NOS), 2026 Congenital Heart Defects 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 1.44 [0.46;4.52] 5/11   52,229/146,202 52,234 11
ref
S8491
R35398		 Miškov (Controls unexposed, disease free), 2016 Congenital heart defect during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 765.00 [11.05;52971.87] C
excluded (control group) 		1/2   0/128 1 2
ref
S8492
R35405		 Miškov (Controls unexposed, sick), 2016 Congenital heart defect during pregnancy (anytime or not specified) excluded prospective cohort unexposed, sick Adjustment: No 21.00 [0.27;1646.32] C
excluded (exposition period) 		1/2   0/4 1 2
ref
S8493
R27900		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Cardiac 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 5.36 [0.58;49.42] C 1/31   4/647 5 31
ref
Total 2 studies 1.94 [0.66;5.70] 52,239 42
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Beau (Gabapentin) (Indications NOS), 2026Beau, 2026 1 1.44[0.46; 4.52]52,2341177%ROB confusion: criticalROB selection: criticalROB classification: unclearROB missing: lowROB mesure: moderateROB reporting: moderate Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 5.36[0.58; 49.42]53123%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 6% 1.94[0.66; 5.70]52,239420.520.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (Indications NOS; 2: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 case control studiescase control studies 1.44[0.46; 4.51]52,23411 -NABeau (Gabapentin) (Indications NOS), 2026 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.44[0.46; 4.51]52,23411 -NABeau (Gabapentin) (Indications NOS), 2026 1 exposed to other treatment, sickexposed to other treatment, sick 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1   - Yes  - Yes 1.44[0.46; 4.51]52,23411 -NABeau (Gabapentin) (Indications NOS), 2026 1 All studiesAll studies 1.94[0.66; 5.70]52,239426%NABeau (Gabapentin) (Indications NOS), 2026 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8491

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.44[0.46; 4.51]52,23411 -NABeau (Gabapentin) (Indications NOS), 2026 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Desrochers (Gabapentin) (Cardiac congenital m ...Desrochers (Gabapentin) (Cardiac congenital malformations) 1.66[1.11; 2.47]68%-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT3 Veroniki a (MA) (All indications) (Cardiac Ma ...Veroniki a (MA) (All indications) (Cardiac Malformations) 8.57[0.26; 162.50]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT2 Veroniki a (NMA) (All indications) (Cardiac m ...Veroniki a (NMA) (All indications) (Cardiac malformations) 5.98[1.34; 19.73]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT-9 Bromley (Gabapentine) (All indications) (Card ...Bromley (Gabapentine) (All indications) (Cardiac Malformations (Cohort studies)) Out of scale129.00[6.49; 2562.48]NA-U,GPunexposed (general population or NOS)Anyduring pregnancy (anytime or not specified)studies TTT1 Bromley (Gabapentine) (All indications) (Card ...Bromley (Gabapentine) (All indications) (Cardiac Malformations (Cohort studies)) 5.00[0.29; 87.54]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bromley (Gabapentine) (All indications) (Card ...Bromley (Gabapentine) (All indications) (Cardiac Malformations (Cohort studies)) 9.57[1.69; 54.15]30%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT2 metaPregmetaPreg 1.94[0.66; 5.70]6%42----Beau (Gabapentin) (Indications NOS), 2026 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0